Sanofi Gets EU Approval
Sanofi's Cenrifki is approved in the EU as the first disability-targeting treatment for non-relapsing secondary progressive multiple sclerosis
· Approval Based On Hercules Phase 3 Study, Supported By Gemini 1 And 2 Phase 3 Studies · Sanofi To Launch Cenrifki Commercially In Germany This Year